HR 4764 116th Congress House Health Advisory bodies Blood and blood diseases Cell biology and embryology Congressional oversight Government studies and investigations Health programs administration and funding Medical research Organ and tissue donation and transplantation Research administration and funding

TRANSPLANT Act of 2020

Introduced: October 18, 2019 Introduced by: Matsui, Doris O. Democratic · California See on congress.gov

Everywhere this bill has been 20 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Dec 14, 2020

Message on Senate action sent to the House.

Dec 11, 2020

Passed Senate with an amendment by Voice Vote. (text of amendment in the nature of a substitute: CR S7450-7451)

Dec 11, 2020

Passed/agreed to in Senate: Passed Senate with an amendment by Voice Vote.(text of amendment in the nature of a substitute: CR S7450-7451)

Dec 11, 2020

Measure laid before Senate by unanimous consent. (consideration: CR S7450-7451)

Oct 1, 2020

Received in the Senate, read twice.

Sep 30, 2020

Motion to reconsider laid on the table Agreed to without objection.

Sep 30, 2020

On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 414 - 0 (Roll no. 211). (text: CR 09/29/2020 H4996)

Sep 30, 2020

Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 414 - 0 (Roll no. 211).

Sep 30, 2020

Considered as unfinished business. (consideration: CR H5089-5090)

Sep 29, 2020

At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.

Sep 29, 2020

DEBATE - The House proceeded with forty minutes of debate on H.R. 4764.

Sep 29, 2020

Considered under suspension of the rules. (consideration: CR H4996-4998)

Sep 29, 2020

Mr. Pallone moved to suspend the rules and pass the bill, as amended.

Sep 29, 2020

Placed on the Union Calendar, Calendar No. 449.

Sep 29, 2020

Reported by the Committee on Energy and Commerce. H. Rept. 116-549.

Sep 9, 2020

Ordered to be Reported by Voice Vote.

Sep 9, 2020

Committee Consideration and Mark-up Session Held.

Oct 21, 2019

Referred to the Subcommittee on Health.

Oct 18, 2019

Referred to the House Committee on Energy and Commerce.

Oct 18, 2019

Introduced in House

Votes taken on this bill 1

Date	Chamber	What was voted on	Result	Yes–No
Sep 30, 2020	House · vote #211	On Motion to Suspend the Rules and Pass, as Amended	Passed	414–0	See who voted →

Plain-English summary Congressional Research Service

Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2020 or the TRANSPLANT Act of 2020

This bill modifies and reauthorizes through FY2025 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. It also requires research and other activities related to stem cell therapies.

Specifically, the Department of Health and Human Services must conduct a periodic review of the science of using adult stem cells and birthing tissues in therapeutic treatments, and the National Institutes of Health must continue efforts to further the field of regenerative medicine using adult stem cells.

In addition, the Government Accountability Office must examine various issues related to the regenerative medicine workforce.

What's happening now December 14, 2020

Message on Senate action sent to the House.

Committees of jurisdiction 2